TY - JOUR
T1 - Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores – A pooled analysis of RTOG 0129 and 0522
AU - Awan, Musaddiq J.
AU - Gittleman, Haley
AU - Barnholtz-Sloan, Jill
AU - Machtay, Mitchell
AU - Nguyen-Tan, Phuc Felix
AU - Rosenthal, David I.
AU - Schultz, Christopher
AU - Huth, Bradley J.
AU - Thorstad, Wade L.
AU - Frank, Steven J.
AU - Kim, Harold
AU - Foote, Robert L.
AU - Lango, Miriam N.
AU - Shenouda, George
AU - Suntharalingam, Mohan
AU - Harris, Jonathan
AU - Zhang, Qiang
AU - Le, Quynh Thu
AU - Yao, Min
N1 - Publisher Copyright:
© 2021
PY - 2021/5
Y1 - 2021/5
N2 - Objectives: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC). Material and methods: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively. Results: The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c = 0.66, c = 0.66 and c = 0.73, respectively. External validation of these nomograms yielded c = 0.59, c = 0.70, and c = 0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome. Conclusions: We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data.
AB - Objectives: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC). Material and methods: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively. Results: The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c = 0.66, c = 0.66 and c = 0.73, respectively. External validation of these nomograms yielded c = 0.59, c = 0.70, and c = 0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome. Conclusions: We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data.
KW - Chemoradiation
KW - Larynx Cancer
KW - Nomograms
KW - Prognostic Factors
UR - http://www.scopus.com/inward/record.url?scp=85101423773&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2021.105241
DO - 10.1016/j.oraloncology.2021.105241
M3 - Article
C2 - 33640577
AN - SCOPUS:85101423773
SN - 1368-8375
VL - 116
JO - Oral Oncology
JF - Oral Oncology
M1 - 105241
ER -